Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Mauvais-Jarvis Contributes Diabetes Expertise to Major Study on Obesity
Uncategorized

Mauvais-Jarvis Contributes Diabetes Expertise to Major Study on Obesity

By Roger AndersonFeb 12, 2013
Share
Facebook Twitter Email
Franck Mauvais-Jarvis, MD, PhD, associate professor in medicine-endocrinology, focuses his research on the role of reproductive hormones in the maintenance of energy homeostasis in humans. Altered production or action of estrogens and androgens predisposes people to becoming obese and developing diabetes.

A world leader in estrogen and beta-cells, Franck Mauvais-Jarvis, MD, PhD, associate professor in medicine-endocrinology, has contributed his expertise to a project that explores the use of synthetic hormones to combat obesity and related medical conditions. 

Published in Nature Medicine, the study focused on a new treatment option that links two hormones into a single molecule. Using the combination of a hormone from the digestive system and estrogen, investigators were able to prove that the new molecule was more effective than either alone in producing weight loss and other positive benefits, while reducing adverse effects. 

“The marriage between the digestive hormone GLP-1 and estrogen shows unprecedented efficacy to enhance the benefits of GLP-1 while at the same time preventing the side effects of estrogen in male and female mice,” said Mauvais-Jarvis, research director of the Northwestern Comprehensive Center on Obesity. “Although estrogens are FDA approved for postmenopausal therapy, the fear of gynecological cancers in women and prostate cancer in men has stood as a major obstacle in prescribing them for weight loss. This study discusses a way to use the hormone without the adverse effects.”

Mauvais-Jarvis recently received funding from the National Institutes of Health to explore the therapeutic effect of the new molecule on the survival, revascularization, and engraftment of human islets transplanted in a model of type 1 diabetes. 

Type 1 diabetes is caused by the immune system’s destruction of insulin-producing cells in the pancreas, known as beta cells. The process of transplanting human islets, tiny organs in the pancreas that contain beta cells, is the best treatment for type 1 diabetes, but the progressive degradation of transplanted islets has thus far prevented long-term success. 

The loss of beta cell function also causes those with glucose intolerance to develop full-blown type 2 diabetes, an epidemic affecting millions of Americans. 

Because current medications fail to maintain long-term beta-cell function, the discovery of novel drugs is a priority. Over the past decade, Mauvais-Jarvis has helped define the field of estrogen receptor action in pancreatic islets, insulin secretion, and the protection of beta cell function.

“This latest collaboration targeting the metabolic syndrome represents the discovery of a new class of therapeutics,” Mauvais-Jarvis said. “Although our observations with the GLP-1-estrogen conjugate justify translational studies for diabetes and obesity, the multitude of other possible combinations of peptides and small molecules may offer equal promise for other diseases.”

Research
Share. Facebook Twitter Email

Related Posts

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Comments are closed.

Latest News

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.